HALO - ハロザイム・セラピュ―ティクス （Halozyme Therapeutics Inc.）

SAN DIEGO, June 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 8 a.m. PT…

Memes are simply images and videos with humorous text included that tend to spread rapidly across the internet. Combine them with stocks and you get wallstreetbets . That’s where the majority of meme stock information is communicated. For an easier-to-navigate listing of meme stocks investors can go here . That’s where all of the companies discussed below were found. These shares are not risky overall despite the reputation that investing in meme stocks may have. There are a few bets to be sure. But those are substantiated using the reasoning of the commenters which is logical. That said, let’s get into those meme-worthy and investment-grade shares. Nvidia (NVDA) Source: Michael Vi / Shutterstock.com When investing in meme stocks, Nvidia (NASDAQ: NVDA ) is far and away the most talked about stock on memestocks.org. It also happens to be a highly respected firm with a lot of positives worth understanding. Meme stocks have a reputation for being risky. Nvidia, despite being one of the largest companies globally, is certainly risky, too.

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, its Investor Class fund ARTSX returned 7.60%, Advisor Class fund APDSX posted a return of 7.63%, and Institutional Class fund APHSX returned 7.62%, compared to a […]

Thursday''s top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022, following the close of trading. Halozyme will host a conference call on…

Halozyme made a smooth transition from a failed R&D company to a successful royalty company. For the next few years, HALO is on a growth trajectory. Read more here.

Halozyme Therapeutics is well fixed to grow revenues from multiple sources over the balance of this decade and beyond. See why I view HALO as a definite buy.

Halozyme Therapeutics Inc. (NASDAQ:HALO) marked $42.51 per share on Wednesday, up from a previous closing price of $41.30. While Halozyme Therapeutics Inc. has overperformed by 2.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HALO rose by 2.68%, with highs and lows ranging from $52.98 to […]

Halozyme Therapeutics Inc. (NASDAQ:HALO) price is hovering higher on Tuesday, August 16, jumping 0.44% above its previous close. A look at today’s price movement shows that the recent level at last check reads $43.09, with intraday deals fluctuating between $41.81 and $43.58. The company’s 5Y monthly beta was ticking 1.20 while its P/E ratio in … Halozyme Therapeutics Inc. (NASDAQ: HALO): Still A Hot Buy? Read More »

Halozyme Therapeutics Inc. (NASDAQ:HALO) price is hovering higher on Tuesday, August 16, jumping 0.44% above its previous close. A look at today’s price movement shows that the recent level at last check reads $43.09, with intraday deals fluctuating between $41.81 and $43.58. The company’s 5Y monthly beta was ticking 1.20 while its P/E ratio in … Halozyme Therapeutics Inc. (NASDAQ: HALO): Still A Hot Buy? Read More »

Halozyme Therapeutics (HALO) has priced upsized offering of $625M of 1.00% convertible senior unsecured notes due August 15, 2028.The offering was upsized from an originally…

Halozyme Therapeutics Inc (NASDAQ: HALO ) reported Q2 revenue of $152.4 million , +12% Y/Y, surpassing the consensus of $138.78 million. The increase was primarily driven by an increase in royalty revenue primarily attributable to subcutaneous Darzalex (daratumumab) and the addition of product sales due to the Antares Pharma acquisition. Revenue for Q2 included $85.3 million in royalties. Adjusted EPS of $0.53 was … Full story available on Benzinga.com

Halozyme Therapeutics (NASDAQ: HALO ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Halozyme Therapeutics beat estimated earnings by 6.0%, reporting an EPS of $0.53 versus an estimate of $0.5. Revenue was up $15.91 million from the same period last … Full story available on Benzinga.com

Halozyme Therapeutics, Inc. (NASDAQ:NASDAQ:HALO) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations &…